Technology
Health
Pharmaceutical

Gemphire Therapeutics

$1.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-3.93%) Today
+$0.02 (1.59%) After Hours

Why Robinhood?

You can buy or sell GEMP and other stocks, options, ETFs, and crypto commission-free!

About

Gemphire Therapeutics Inc. Common Stock, also called Gemphire Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. Read More It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI.

Employees
9
Headquarters
Livonia, Michigan
Founded
2014
Market Cap
17.83M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
400.69K
High Today
$1.28
Low Today
$1.20
Open Price
$1.27
Volume
12.70K
52 Week High
$11.43
52 Week Low
$0.5698

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2016 IPO
US

Earnings

-$0.99
-$0.75
-$0.50
-$0.26
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.41 per share
Actual
-$0.26 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.